Most cardiovascular outcome trials involving lipid-lowering treatments have only examined participants who had a previous cardiovascular event. As a result, researchers wanted to explore how bempedoic acid affects cardiovascular outcomes among people who are statin-intolerant and have never had a major cardiovascular event such as a heart attack.
